Immunotherapy of cancer using dendritic cells.
While the promise of harnessing the immune system for a therapeutic effect has remained largely unfulfilled for many years, the discovery of the central role of dendritic cells in stimulating antigen-specific immune responses has prompted new enthusiasm for immunotherapy of malignancies. Elucidation of the pathways of dendritic cell development and trafficking, acquisition and processing of antigen, and stimulation of T cells has suggested methods for generating and antigen-loading dendritic cells for use in immunotherapy protocols. Animal models have demonstrated that dendritic cells can stimulate protective antitumor responses in vivo. Phase I clinical trials have been initiated to address the safety and feasibility of immunizations with dendritic cells in humans with various malignancies.
Morse
M A
MA
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA. morse004@mc.duke.edu
Lyerly
H K
HK
D000818:Animals; D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D018448:Models, Immunological; D009369:Neoplasms / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
D000951:Antigens, Neoplasm